Nicolazzo and colleagues [46] monitored CTCs in patients with advanced NSCLC undergoing immunotherapy (nivolumab) in order to determine whether there was an association between PD-L1 expression in CTCs and response to immunotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.